The initial results of the FAVOUR study showed that in advanced EGFR ex20ins NSCLC patients treated with first-line furmonertinib, the IRC-confirmed ORR was 60%, the ORR determined by the investigators was 70%, and the DCR was 100%. This evidence concerns the gene EGFR and non-small cell lung carcinoma.